Hydroxyurea Resistant Polycythemia Vera Hydroxyurea Resistant Polycythemia Vera
January 2015
A 39-year-old male presents with headache and weight loss He is a 2-pack a day smoker PMH includes type 2 diabetes, moderately controlled on medication; newly-diagnosed hypertension Physical exam: BP, 176/94, otherwise unremarkable Laboratory values:Hb; 233 g/L Hct; 68.9%; Mean corpusc. vol.; 81 fL Leukocytes; 4.4 × 109 /L Platelets; 145 × 109 /L Bone marrow biopsy;MF-3 fibrosis and megakaryocytic hyperplasia with atypia Normal karyotype JAK2 -positive Patient was started on phlebotomy as needed and aspirin
April 2015
Patient had 3 phlebotomies in the last 3 months. He reported increasing dizziness, headaches and nausea He was continued on phlebotomy as needed; aspirin was continued Patient was started on Hydroxyurea 1000 mg daily
July 2015
Patient comes back 3 months later, he has had 2 phlebotomies Hydroxyurea is increased to 1500 mg
October 2015
Patient returns 3 months later with pruritus, still requiring phlebotomy He is started on hydroxyurea 2000 mg daily
January 2016
The patient has had 2 phlebotomies since his last visit; he reports abdominal fullness He also has restless legs and is complaining that food tastes funny Spleen is palpable 7 cm below costal margin
Newsletter Stay up to date on practice-changing data in community practice.
Subscribe
November 8th, 2026 Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
November 8th, 2026 Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
November 8th, 2026 Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
November 7th, 2026 Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
November 7th, 2026 Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
November 7th, 2026 Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
November 7th, 2026 Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
November 7th, 2026 Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.